Table 1 Clinicopathological characteristics of patients before and after propensity score matching

Age (years)

≤70

37 (60.7)

95 (77.9)

0.014^a

37 (64.9)

41 (71.9)

0.420^a

>70

24 (39.3)

27 (22.1)

20 (35.1)

16 (28.1)

Gender

Male

40 (65.6)

75 (61.5)

0.589^a

39 (68.4)

37 (64.9)

0.691^a

Female

21 (34.4)

47 (38.5)

18 (31.6)

20 (35.1)

ASA grade

I–II

50 (82.0)

107 (87.7)

0.295^a

47 (82.5)

45 (79.0)

0.635^a

III

11 (18.0)

15 (12.3)

10 (17.5)

12 (21.0)

16 (26.2)

20 (16.4)

0.115^a

14 (24.6)

12 (21.1)

0.655^a

Tumor location

RSC

21 (34.4)

69 (56.6)

0.005^a

21 (36.8)

23 (40.4)

0.700^a

UR

40 (65.6)

53 (43.4)

36 (63.2)

34 (59.7)

23.4

23.9

0.243^b

23.4

24.0

0.903^b

(18.3–34.9)

(15.2–33.4)

(18.3–30.1)

(17.3–30.8)

4.0 (3.0–6.0)

4.0 (2.5–9.0)

0.143^b

4.0 (3.0–6.0)

4.0 (2.5–9.0)

0.505^b

5.1 (0.2–9.5)

3.7 (0.5–13.0)

0.005^b

5.0 (0.2–9.5)

5.0 (0.5–13.0)

0.803^b

Histology

WD/MD

58 (95.1)

118 (96.7)

0.688^c

55 (96.5)

55 (96.5)

1.000^c

PD

3 (4.9)

4 (3.3)

2 (3.5)

2 (3.5)

Stage

I

12 (19.7)

37 (30.3)

0.387^c

12 (21.1)

12 (21.1)

0.886^c

II

16 (26.2)

31 (25.4)

16 (28.1)

13 (22.8)

III

31 (50.8)

52 (42.7)

28 (49.1)

30 (52.6)

IV

2 (3.3)

2 (1.6)

1 (1.8)

2 (3.5)